ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Dise...
May 08 2019 - 7:00AM
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage
biotechnology company focused on the discovery and development of
biologic therapies for life-threatening, drug-resistant infectious
diseases, today announced that it will host an R&D Symposium
with widely recognized infectious disease clinicians on the
broad potential of direct lytic agents as anti-infectives, with a
focus on the methicillin-resistant Staphylococcus aureus (MRSA)
data from the Phase 2 trial of exebacase, on Tuesday, May 14,
2019, at 8:30 a.m. EDT in New York.
The event will be led by Roger Pomerantz, M.D., F.A.C.P.,
President, Chief Executive Officer and Chairman of ContraFect and
will feature presentations from Vance G. Fowler, M.D., Professor of
Medicine in the Division of Infectious Diseases at Duke University,
and G. Ralph Corey, M.D., Professor of Medicine in the Division of
Infectious Diseases, Vice Chair for Education and Global Health in
the School of Medicine, Gary Hock Professor of Global Health, and
Director of the Hubert-Yeargan Center for Global Health at Duke
University. Members of ContraFect’s management team, Cara
Cassino, M.D., the Chief Medical Officer and EVP of Research and
Development and Raymond Schuch, Ph.D., the Vice President of
Research, will provide an in-depth review of the data from the
exebacase Phase 2 study and an overview of the Company’s discovery
programs targeted towards Gram-negative pathogens.
A live webcast of the event will be available on the Investors
& Media section of the Company’s website at www.contrafect.com.
The presentation will also be available as an archived webcast for
a limited time.
About ContraFect
ContraFect is a biotechnology company focused on discovering and
developing differentiated biologic therapies for life-threatening,
drug-resistant infectious diseases, particularly those treated in
hospital settings. An estimated 700,000 deaths worldwide each year
are attributed to antimicrobial-resistant infections. We intend to
address life threatening infections using our therapeutic product
candidates from our lysin platform and through the use of other
novel agents. Lysins are a new therapeutic class of
bacteriophage-derived, recombinantly produced, antimicrobial
proteins with a novel mechanism of action associated with the rapid
killing of target bacteria, eradication of biofilms and synergy
with conventional antibiotics. We believe that the properties of
our lysins will make them suitable for targeting
antibiotic-resistant organisms, such as Staph aureus and
Pseudomonas aeruginosa (P. aeruginosa), which can cause serious
infections such as bacteremia, pneumonia and osteomyelitis. Our
lead lysin candidate, exebacase is completing a Phase 2 clinical
trial for the treatment of Staph aureus bacteremia, including
endocarditis and is the first lysin to enter clinical studies in
the U.S.
Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.
Forward-Looking Statements
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding the Company’s
ability to discover and develop biological therapies for
life-threatening, drug-resistant infectious diseases, statements
made regarding the R&D Symposium, whether Dr. Fowler and Dr.
Corey are widely recognized infectious disease clinicians, whether
direct lytic agents have the broad potential to be anti-infectives,
statements regarding Phase 2 study data and MRSA data, the
Company’s ability to address life threatening infections using its
therapeutic product candidates from its lysin platform and through
the use of other novel agents, whether lysins are a new therapeutic
class of bacteriophage-derived, recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics, and whether the
properties of the Company’s lysins will make them suitable for
targeting antibiotic-resistant organisms, such as Staph aureus and
P. aeruginosa. Forward-looking statements are statements that are
not historical facts, nor assurances of future performance.
Instead, they are based on ContraFect’s current beliefs,
expectations and assumptions regarding the future of its business,
future plans, strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including those detailed in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ
from those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations Contacts
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024